[go: up one dir, main page]

MX2023007420A - Tratamiento de glomerulopatia c3 usando un inhibidor de c5a. - Google Patents

Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.

Info

Publication number
MX2023007420A
MX2023007420A MX2023007420A MX2023007420A MX2023007420A MX 2023007420 A MX2023007420 A MX 2023007420A MX 2023007420 A MX2023007420 A MX 2023007420A MX 2023007420 A MX2023007420 A MX 2023007420A MX 2023007420 A MX2023007420 A MX 2023007420A
Authority
MX
Mexico
Prior art keywords
glomerulopathy
inhibitor
treatment
susceptible
administering
Prior art date
Application number
MX2023007420A
Other languages
English (en)
Inventor
Peter Staehr
Petrus J Bekker
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2023007420A publication Critical patent/MX2023007420A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para tratar ciertas poblaciones de pacientes humanos que sufren de glomerulopatía C3 o son susceptibles a ella, que comprenden la administración al ser humano de una cantidad eficaz de un antagonista de C5aR.
MX2023007420A 2020-12-21 2021-12-20 Tratamiento de glomerulopatia c3 usando un inhibidor de c5a. MX2023007420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128397P 2020-12-21 2020-12-21
PCT/US2021/064350 WO2022140258A1 (en) 2020-12-21 2021-12-20 Treatment of c3 glomerulopathy using a c5a inhibitor

Publications (1)

Publication Number Publication Date
MX2023007420A true MX2023007420A (es) 2023-06-29

Family

ID=82159849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007420A MX2023007420A (es) 2020-12-21 2021-12-20 Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.

Country Status (12)

Country Link
US (1) US20220257580A1 (es)
EP (1) EP4262800A4 (es)
JP (1) JP2024500752A (es)
KR (1) KR20230124981A (es)
CN (1) CN116635075A (es)
AU (1) AU2021410668A1 (es)
CA (1) CA3205474A1 (es)
CL (1) CL2023001836A1 (es)
IL (1) IL303776A (es)
MX (1) MX2023007420A (es)
TW (1) TW202241423A (es)
WO (1) WO2022140258A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926828T3 (es) 2014-09-29 2022-10-28 Chemocentryx Inc Procesos e intermedios en la preparación de antagonistas de C5aR
JP7339733B2 (ja) 2016-01-14 2023-09-06 ケモセントリックス，インコーポレイティド Ｃ３腎症を処置する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2994488B1 (en) * 2013-05-08 2022-07-13 Novo Nordisk A/S Use of c5ar antagonists
JP7339733B2 (ja) * 2016-01-14 2023-09-06 ケモセントリックス，インコーポレイティド Ｃ３腎症を処置する方法
WO2017176620A2 (en) * 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
KR102754341B1 (ko) * 2016-11-23 2025-01-13 케모센트릭스, 인크. 국소 분절 사구체경화증의 치료 방법
CN111670185A (zh) * 2017-10-31 2020-09-15 凯莫森特里克斯股份有限公司 减少尿sCD163的C5aR抑制剂
EP3728203B1 (en) * 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
US10759807B2 (en) * 2017-12-22 2020-09-01 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
ES2993034T3 (en) * 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists
SG11202105572UA (en) * 2018-11-30 2021-06-29 Chemocentryx Inc Capsule formulations

Also Published As

Publication number Publication date
IL303776A (en) 2023-08-01
AU2021410668A1 (en) 2023-07-06
US20220257580A1 (en) 2022-08-18
CL2023001836A1 (es) 2023-11-17
AU2021410668A9 (en) 2024-08-01
KR20230124981A (ko) 2023-08-28
JP2024500752A (ja) 2024-01-10
CA3205474A1 (en) 2022-06-30
EP4262800A4 (en) 2024-11-20
CN116635075A (zh) 2023-08-22
WO2022140258A1 (en) 2022-06-30
TW202241423A (zh) 2022-11-01
EP4262800A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
MX2022000143A (es) Metodos novedosos.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
DE60336821D1 (de) Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung
BR112022024483A2 (pt) Métodos para tratar mieloma múltiplo
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
AR119158A1 (es) Tratamientos de angioedema hereditario
MX2024008461A (es) Metodos para tratar trastornos linfoproliferativos malignos.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2023007420A (es) Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.
MX2022000812A (es) Metodos de tratamiento de hiperplasia suprarrenal congenita.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
MX2020011817A (es) Metodos para tratar el linfoma.
MX2024000986A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus.
MA69153A1 (fr) Méthodes de traitement d'une splénomégalie
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
AR119159A1 (es) Tratamientos de angioedema
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
BR112022001699A2 (pt) Métodos e composições para reduzir imunogenicidade através de inibidores não deplecionais de célula b
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
ZA202103914B (en) Cxcr7 inhibitors for the treatment of cancer
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.